FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Nexlizet, the fixed-dose combination of bempedoic acid and ezetimibe from Esperion Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• NEXLIZET (bempedoic acid and ezetimibe)

Snippet

SUPPL AP for NEXLIZET (BEMPEDOIC ACID AND EZETIMIBE)